StudyRareStudyRare
Log in to add personal notes on this page.

A teenage boy has painful burning in hands and feet (acroparesthesias), inability to sweat, and angiokeratomas on his trunk. His mother has mild symptoms.

XLR; GLA (alpha-galactosidase A, a lysosomal enzyme that removes the terminal galactose from Gb3). Loss-of-function variants; heterozygous females range from unaffected to as severe as males with X-inactivation.

Alpha-galactosidase A removes the terminal galactose from globotriaosylceramide (Gb3). When activity falls, Gb3 and especially its deacylated form, lyso-Gb3, accumulate in plasma, urine, and the lysosomes of many cells: the autonomic nervous system and dorsal root ganglia, kidney epithelium including podocytes, blood vessels, and heart muscle. Those are the tissues behind the pain crises and sweating abnormalities, the proteinuria that leads to kidney failure in the third to fifth decade, and the cardiac disease. Storage disturbs cell signaling, calcium handling, mitochondrial energy metabolism, and autophagy, triggers inflammation, and damages the endothelium, which drives the stroke and cardiovascular disease; cardiovascular disease is the most common cause of death.

Variant class sets residual activity:

  • Classic phenotype (males with under 1% activity): rearrangements, splice defects, nonsense, frameshift, and missense variants at the active site.
  • Later-onset cardiac, renal, or cerebrovascular disease: missense or splice variants that keep some activity, such as p.Asn215Ser and the Taiwanese founder c.640-801G>A.

Many missense variants misfold the enzyme, which is then held back from the lysosome. That is the target of migalastat, a chaperone that protects amenable mutant enzyme from misfolding and degradation.

alpha-galactosidase AGLAFabry diseaseGM1 beta-galactosidase orgalactocerebrosidaseGLB1, GALCglobotriaosyl-ceramide (Gb3)lactosylceramideglucosylceramide
Excerpt from lysosomal sphingolipid degradation. See the full pathway.

Part of lysosomal sphingolipid degradation.

Lysosomal sphingolipid (glycosphingolipid) degradation.

globotriaosylceramide (Gb3) → alpha-galactosidase A (the block; removes terminal galactose) → lactosylceramide → glucosylceramide → ceramide

  • Accumulates: Gb3 and lyso-Gb3, measured as plasma lyso-Gb3, which correlates with treatment response.
  • Missing: clearance of Gb3; the injury comes from storage in nerve, kidney, heart, and vessel wall.
  • Workbook: 7.C. Gaucher type 1 and Fabry disease
  • Alpha-galactosidase A deficiency → Gb3 accumulation
  • Pain: Acroparesthesias (hands/feet), triggered by heat/exercise
  • Skin: Angiokeratomas (clustered on trunk, "bathing suit" distribution)
  • Ocular: Corneal verticillata (whorl-like opacities)
  • Renal: Progressive renal failure
  • Cardiac: LVH, arrhythmias
  • CNS: Stroke (young adult)
  • Females can be significantly affected

References: GeneReviews | Pediatric Management (2015) | Adult Management (2018)

  • Not on the RUSP: proposed in 2008 and rejected by the federal advisory committee over test sensitivity, later-onset variants, and unproven benefit of early treatment. Several states screen newborns anyway, flagged by low alpha-galactosidase A activity
  • Males: deficient alpha-galactosidase A enzyme activity is diagnostic, confirmed with GLA sequencing
  • Females: enzyme activity can be normal (random X-inactivation), so GLA molecular testing is required
  • Elevated plasma globotriaosylsphingosine (lyso-Gb3) supports the diagnosis and tracks disease burden
  • Enzyme replacement therapy (agalsidase), migalastat (chaperone for amenable variants)

"Park your Car in the Garage": the risk for Parkinson's disease is increased in Carriers of Gaucher disease. This is a clinically important association that helps distinguish Gaucher from Fabry (both are sphingolipidoses).

Gaucher disease mnemonic: "Park your Car in the Garage". Parkinson's risk is increased in carriers of Gaucher disease
Gaucher disease mnemonic: "Park your Car in the Garage". Parkinson's risk is increased in carriers of Gaucher disease

FABRY: Feel the Burn, Angiokeratoma, Renal: covers the triad of acroparesthesias (burning pain), skin findings, and progressive renal failure.

"FabRY mainly affects Y chromosomes (boys)": Fabry is X-linked, so males are primarily affected.

"Spray Fabreze on Ceramic Tiles": ceramide trihexoside (Gb3) accumulates. Also: Fabry lives Far into the future (death from ESRD in 40s, unlike infantile-onset lysosomal disorders).

All sphingolipidoses are AR except Fabry (XL): Fabry is the only X-linked sphingolipidosis. It is not the only X-linked lysosomal disorder: Hunter syndrome (MPS II) is X-linked too.

This diagram shows the enzymatic defect in Fabry disease: alpha-galactosidase A cleaves the terminal galactose from globotriaosylceramide (Gb3) to produce lactosylceramide.

Fabry disease biochemical pathway: alpha-galactosidase A deficiency prevents conversion of Gb3 (globotriaosylceramide) to lactosylceramide by failing to cleave the terminal alpha-linked galactose
Fabry disease biochemical pathway: alpha-galactosidase A deficiency prevents conversion of Gb3 (globotriaosylceramide) to lactosylceramide by failing to cleave the terminal alpha-linked galactose